Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has results × ALK+ Advanced NSCLC × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1691 Neoplasms 1211 Carcinoma, Non-Small-Cell Lung 1118 Prostatic Neoplasms 936 Multiple Myeloma 731 Leukemia, Myeloid, Acute 655 Neoplasm Metastasis 614 Colorectal Neoplasms 588 Lung Neoplasms 577 Melanoma 573 Lymphoma 570 Leukemia 520 Lymphoma, Non-Hodgkin 498 Leukemia, Lymphocytic, Chronic, B-Cell 461 Ovarian Neoplasms 453 Pancreatic Neoplasms 437 Precursor Cell Lymphoblastic Leukemia-Lymphoma 409 Recurrence 402 Myelodysplastic Syndromes 364 Lymphoma, Follicular 354 Head and Neck Neoplasms 339 Glioblastoma 333 Carcinoma, Renal Cell 331 Brain Neoplasms 331 Lymphoma, Large B-Cell, Diffuse 320 Hodgkin Disease 295 Carcinoma, Hepatocellular 291 Squamous Cell Carcinoma of Head and Neck 268 Lymphoma, Mantle-Cell 267 Sarcoma 242

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡